Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Projec...

Full description

Saved in:
Bibliographic Details
Published in:Annals of neurology 2024-04, Vol.95 (4), p.625-634
Main Authors: Vance, Jeffery M, Farrer, Lindsay A, Huang, Yadong, Cruchaga, Carlos, Hyman, Bradley T, Pericak-Vance, Margaret A, Goate, Alison M, Greicius, Michael D, Griswold, Anthony J, Haines, Jonathan L, Tcw, Julia, Schellenberg, Gerard D, Tsai, Li-Huei, Herz, Joachim, Holtzman, David M
Format: Article
Language:English
Subjects:
Aging
Alzheimer's disease
Animal models
Apolipoprotein E4
E4 gene
Neurodegenerative diseases
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625-634.
ISSN:0364-5134
1531-8249
DOI:10.1002/ana.26864